JUN 08, 2020 3:02 PM PDT

Using Soft Tissue Sarcoma's Immune Defense as a Biomarker

WRITTEN BY: Jasper Cantrell

Programmed cell death protein 1 (PD-1) has been a big player in the treatment of both autoimmune disease and cancer. PD-1 is a receptor on the cell membrane that promotes cellular apoptosis, or cell death, in T-cells. It also prevents apoptosis in regulatory T-cells, which usually suppresses the immune response. Programmed death-ligand 1 (PD-L1) Is the trigger factor that initiates PD-1 signaling. Many cancers overexpress PD-L1, which creates an immunosuppressive environment and protects the tumor from the innate anti-cancer immune response. PD-1 inhibitors have had success in preventing this, promoting anti-cancer activity through the innate immune response.

Although these interactions are well studied in many cancer types, this not the case for soft tissue sarcomas (STSs). STSs are rare malignant neoplasms, with as many as 40% of patients seeing metastatic recurrence post-operation. A team from the Mie University School of Medicine in Japan hypothesized that the blood soluble PD-L1 (sPD-L1) would create an immunosuppressive environment around STS tumors and could be used as a prognostic biomarker in STS treatment.

Using data from 135 STS patients enrolled in the program at the university, the team began their analysis. The first observation they made was that compared to healthy volunteers, STS, and benign tumor patients had increased PD-L1 levels overall. Benign and STS tumors did not have a significant difference in sPD-L1 levels, however. Late-stage STS patients who developed metastasis, as well as those who unfortunately passed, were observed to have higher sPD-L1 concentrations than the rest of the patient group. Statistical analysis confirmed the correlation of high sPD-L1 levels and a low metastatic-free survival and overall-survival rate in patients with late-stage STSs.

The results of this study were not the clearest support of sPD-L1 and STS prognosis. Late-stage STS patients were the only patients with a clear correlation between sPD-L1 levels and overall survival rates or metastasis-free survival rates. The team admits to the limitations of the relatively small patient group, with possible bias from the large number of late-stage STSs. The type of STSs ranged across twenty sub-types as well, possibly clouding the data. Even with these limitations, the results show that sPD-L1 may be a useful biomarker for late-stage STS prognosis, and further study might reveal even more uses.

Sources: Nature, ImmunoOncology

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
SEP 14, 2020
Cancer
MiR-107 and Its Role in Radiosensitivity in Prostate Cancer
SEP 14, 2020
MiR-107 and Its Role in Radiosensitivity in Prostate Cancer
It is often unknown whether a patient will respond to a treatment until it is in full swing. New research is attempting ...
OCT 06, 2020
Cannabis Sciences
Cannabis Use May Reduce Cancer Risk by 10%
OCT 06, 2020
Cannabis Use May Reduce Cancer Risk by 10%
A recent meta-analysis of 34 studies found that cannabis use may decrease one’s risk of developing certain kinds o ...
OCT 29, 2020
Cancer
Eat until you are only 70% full to reduce risk of fatty liver and liver cancer
OCT 29, 2020
Eat until you are only 70% full to reduce risk of fatty liver and liver cancer
Non-alcoholic fatty liver disease is known to be a risk factor for liver cancer because of an excess of fat accumulation ...
NOV 02, 2020
Cancer
Using an Anti-Malarial Drug to Fight Cancer
NOV 02, 2020
Using an Anti-Malarial Drug to Fight Cancer
Modern pharmaceutical companies spend billions of dollars and years of time developing the next big drug. What if they d ...
NOV 06, 2020
Drug Discovery & Development
Anti-depressant Shows Promise in Treating Childhood Cancer
NOV 06, 2020
Anti-depressant Shows Promise in Treating Childhood Cancer
Researchers from Sweden and the US have found that a commonly prescribed antidepressant may help stop the growth of a ca ...
NOV 07, 2020
Cancer
Newly identified biomarker sheds light on antiangiogenic drug responses
NOV 07, 2020
Newly identified biomarker sheds light on antiangiogenic drug responses
A study published last week in the journal EMBO Molecular Medicine provides insight into the molecular mechanisms t ...
Loading Comments...